These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 37407548)

  • 21. Depletion of AADC activity in caudate nucleus and putamen of Parkinson's disease patients; implications for ongoing AAV2-AADC gene therapy trial.
    Ciesielska A; Samaranch L; San Sebastian W; Dickson DW; Goldman S; Forsayeth J; Bankiewicz KS
    PLoS One; 2017; 12(2):e0169965. PubMed ID: 28166239
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [3H]Nitrendipine binding sites are decreased in the substantia nigra and striatum of the brain from patients with Parkinson's disease.
    Nishino N; Noguchi-Kuno SA; Sugiyama T; Tanaka C
    Brain Res; 1986 Jul; 377(1):186-9. PubMed ID: 2942224
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Alterations of miRNAs reveal a dysregulated molecular regulatory network in Parkinson's disease striatum.
    Nair VD; Ge Y
    Neurosci Lett; 2016 Aug; 629():99-104. PubMed ID: 27369327
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Decreased serum ceruloplasmin levels characteristically aggravate nigral iron deposition in Parkinson's disease.
    Jin L; Wang J; Zhao L; Jin H; Fei G; Zhang Y; Zeng M; Zhong C
    Brain; 2011 Jan; 134(Pt 1):50-8. PubMed ID: 21109502
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Decreased binding of the D3 dopamine receptor-preferring ligand [11C]-(+)-PHNO in drug-naive Parkinson's disease.
    Boileau I; Guttman M; Rusjan P; Adams JR; Houle S; Tong J; Hornykiewicz O; Furukawa Y; Wilson AA; Kapur S; Kish SJ
    Brain; 2009 May; 132(Pt 5):1366-75. PubMed ID: 19153147
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Correlation of dopaminergic terminal dysfunction and microstructural abnormalities of the basal ganglia and the olfactory tract in Parkinson's disease.
    Scherfler C; Esterhammer R; Nocker M; Mahlknecht P; Stockner H; Warwitz B; Spielberger S; Pinter B; Donnemiller E; Decristoforo C; Virgolini I; Schocke M; Poewe W; Seppi K
    Brain; 2013 Oct; 136(Pt 10):3028-37. PubMed ID: 24014521
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Brain alpha-synuclein accumulation in multiple system atrophy, Parkinson's disease and progressive supranuclear palsy: a comparative investigation.
    Tong J; Wong H; Guttman M; Ang LC; Forno LS; Shimadzu M; Rajput AH; Muenter MD; Kish SJ; Hornykiewicz O; Furukawa Y
    Brain; 2010 Jan; 133(Pt 1):172-88. PubMed ID: 19903734
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The relation of putamen and caudate nucleus 18F-Dopa uptake to motor and cognitive performances in Parkinson's disease.
    Broussolle E; Dentresangle C; Landais P; Garcia-Larrea L; Pollak P; Croisile B; Hibert O; Bonnefoi F; Galy G; Froment JC; Comar D
    J Neurol Sci; 1999 Jul; 166(2):141-51. PubMed ID: 10475108
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study.
    Simuni T; Uribe L; Cho HR; Caspell-Garcia C; Coffey CS; Siderowf A; Trojanowski JQ; Shaw LM; Seibyl J; Singleton A; Toga AW; Galasko D; Foroud T; Tosun D; Poston K; Weintraub D; Mollenhauer B; Tanner CM; Kieburtz K; Chahine LM; Reimer A; Hutten SJ; Bressman S; Marek K;
    Lancet Neurol; 2020 Jan; 19(1):71-80. PubMed ID: 31678032
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mapping microstructural gradients of the human striatum in normal aging and Parkinson's disease.
    Drori E; Berman S; Mezer AA
    Sci Adv; 2022 Jul; 8(28):eabm1971. PubMed ID: 35857492
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Alterations in brain opiate receptors in Parkinson's disease.
    Reisine TD; Rossor M; Spokes E; Iversen LL; Yamamura HI
    Brain Res; 1979 Sep; 173(2):378-82. PubMed ID: 226215
    [No Abstract]   [Full Text] [Related]  

  • 32. Brain monoamines in progressive supranuclear palsy--comparison with idiopathic Parkinson's disease.
    Hornykiewicz O; Shannak K
    J Neural Transm Suppl; 1994; 42():219-27. PubMed ID: 7964689
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Longitudinal evolution of compensatory changes in striatal dopamine processing in Parkinson's disease.
    Nandhagopal R; Kuramoto L; Schulzer M; Mak E; Cragg J; McKenzie J; McCormick S; Ruth TJ; Sossi V; de la Fuente-Fernandez R; Stoessl AJ
    Brain; 2011 Nov; 134(Pt 11):3290-8. PubMed ID: 22075521
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The fate of striatal dopaminergic neurons in Parkinson's disease and Huntington's chorea.
    Huot P; Lévesque M; Parent A
    Brain; 2007 Jan; 130(Pt 1):222-32. PubMed ID: 17142832
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Expression of tyrosine hydroxylase isoforms and phosphorylation at serine 40 in the human nigrostriatal system in Parkinson's disease.
    Shehadeh J; Double KL; Murphy KE; Bobrovskaya L; Reyes S; Dunkley PR; Halliday GM; Dickson PW
    Neurobiol Dis; 2019 Oct; 130():104524. PubMed ID: 31276794
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Brain monoamine oxidase B and A in human parkinsonian dopamine deficiency disorders.
    Tong J; Rathitharan G; Meyer JH; Furukawa Y; Ang LC; Boileau I; Guttman M; Hornykiewicz O; Kish SJ
    Brain; 2017 Sep; 140(9):2460-2474. PubMed ID: 29050386
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Increased striatal pre-proenkephalin B expression is associated with dyskinesia in Parkinson's disease.
    Henry B; Duty S; Fox SH; Crossman AR; Brotchie JM
    Exp Neurol; 2003 Oct; 183(2):458-68. PubMed ID: 14552886
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sleep benefit in patients with Parkinson's disease is associated with the dopamine transporter expression in putamen.
    Wang RF; Li YP; Zhang HY; Xu SS; Wang Z; Han XM; Liu BP
    Brain Res; 2023 Mar; 1802():148173. PubMed ID: 36460060
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Differential diagnosis of Parkinson's disease, multiple system atrophy, and Steele-Richardson-Olszewski syndrome: discriminant analysis of striatal 18F-dopa PET data.
    Burn DJ; Sawle GV; Brooks DJ
    J Neurol Neurosurg Psychiatry; 1994 Mar; 57(3):278-84. PubMed ID: 8158173
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Proton MR spectroscopic imaging of the striatum in Parkinson's disease.
    Cruz CJ; Aminoff MJ; Meyerhoff DJ; Graham SH; Weiner MW
    Magn Reson Imaging; 1997; 15(6):619-24. PubMed ID: 9285801
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.